{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:58:32Z","timestamp":1778918312830,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Autologous tumor cell-based vaccines (ATVs) aim to prevent and treat tumor metastasis by activating patient-specific tumor antigens to induce immune memory. However, their clinical efficacy is limited. Mannan-BAM (MB), a pathogen-associated molecular pattern (PAMP), can coordinate an innate immune response that recognizes and eliminates mannan-BAM-labeled tumor cells. TLR agonists and anti-CD40 antibodies (TA) can enhance the immune response by activating antigen-presenting cells (APCs) to present tumor antigens to the adaptive immune system. In this study, we investigated the efficacy and mechanism of action of rWTC-MBTA, an autologous whole tumor cell vaccine consisting of irradiated tumor cells (rWTC) pulsed with mannan-BAM, TLR agonists, and anti-CD40 antibody (MBTA), in preventing tumor metastasis in multiple animal models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The efficacy of the rWTC-MBTA vaccine was evaluated in mice using breast (4T1) and melanoma (B16-F10) tumor models via subcutaneous and intravenous injection of tumor cells to induce metastasis. The vaccine\u2019s effect was also assessed in a postoperative breast tumor model (4T1) and tested in autologous and allogeneic syngeneic breast tumor models (4T1 and EMT6). Mechanistic investigations included immunohistochemistry, immunophenotyping analysis, ELISA, tumor-specific cytotoxicity testing, and T-cell depletion experiments. Biochemistry testing and histopathology of major tissues in vaccinated mice were also evaluated for potential systemic toxicity of the vaccine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The rWTC-MBTA vaccine effectively prevented metastasis and inhibited tumor growth in breast tumor and melanoma metastatic animal models. It also prevented tumor metastasis and prolonged survival in the postoperative breast tumor animal model. Cross-vaccination experiments revealed that the rWTC-MBTA vaccine prevented autologous tumor growth, but not allogeneic tumor growth. Mechanistic data demonstrated that the vaccine increased the percentage of antigen-presenting cells, induced effector and central memory cells, and enhanced CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T-cell responses. T-cells obtained from mice that were vaccinated displayed tumor-specific cytotoxicity, as shown by enhanced tumor cell killing in co-culture experiments, accompanied by increased levels of Granzyme B, TNF-\u03b1, IFN-\u03b3, and CD107a in T-cells. T-cell depletion experiments showed that the vaccine\u2019s antitumor efficacy depended on T-cells, especially CD4<jats:sup>+<\/jats:sup> T-cells. Biochemistry testing and histopathology of major tissues in vaccinated mice revealed negligible systemic toxicity of the vaccine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The rWTC-MBTA vaccine demonstrated efficacy in multiple animal models through T-cell mediated cytotoxicity and has potential as a therapeutic option for preventing and treating tumor metastasis with minimal systemic toxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-023-02744-8","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T03:19:07Z","timestamp":1689131947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses"],"prefix":"10.1186","volume":"42","author":[{"given":"Juan","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelio","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samik","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyu","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Uher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Zenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-7370","authenticated-orcid":false,"given":"Zhengping","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"4","key":"2744_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/ncponc1066","volume":"5","author":"PS Steeg","year":"2008","unstructured":"Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol. 2008;5(4):206\u201319.","journal-title":"Nat Clin Pract Oncol"},{"issue":"4","key":"2744_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000447549","volume":"11","author":"C Liedtke","year":"2016","unstructured":"Liedtke C, Kolberg HC. Systemic therapy of Advanced\/Metastatic breast Cancer - current evidence and future concepts. Breast Care (Basel). 2016;11(4):275\u201381.","journal-title":"Breast Care (Basel)"},{"key":"2744_CR3","doi-asserted-by":"crossref","unstructured":"Schaller J, Agudo J. Metastatic colonization: escaping Immune Surveillance. Cancers (Basel). 2020;12(11).","DOI":"10.3390\/cancers12113385"},{"issue":"4","key":"2744_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/00000658-200210000-00015","volume":"236","author":"PB Paty","year":"2002","unstructured":"Paty PB, Nash GM, Baron P, Zakowski M, Minsky BD, Blumberg D, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236(4):522\u201329. discussion 9\u201330.","journal-title":"Ann Surg"},{"issue":"4","key":"2744_CR5","first-page":"242","volume":"3","author":"H Uramoto","year":"2014","unstructured":"Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242\u20139.","journal-title":"Transl Lung Cancer Res"},{"issue":"7378","key":"2744_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139.","journal-title":"Nature"},{"issue":"13","key":"2744_CR7","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-07-0588","volume":"13","author":"J Schlom","year":"2007","unstructured":"Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007;13(13):3776\u201382.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2744_CR8","doi-asserted-by":"publisher","first-page":"e23403","DOI":"10.4161\/onci.23403","volume":"2","author":"K Yaddanapudi","year":"2013","unstructured":"Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: looking to the future. Oncoimmunology. 2013;2(3):e23403.","journal-title":"Oncoimmunology"},{"key":"2744_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.","journal-title":"BMC Med"},{"key":"2744_CR10","doi-asserted-by":"crossref","unstructured":"Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018;10(436).","DOI":"10.1126\/scitranslmed.aao5931"},{"issue":"1","key":"2744_CR11","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.1038\/s41467-022-33831-7","volume":"13","author":"Y Guo","year":"2022","unstructured":"Guo Y, Wang SZ, Zhang X, Jia HR, Zhu YX, Zhang X, et al. In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses. Nat Commun. 2022;13(1):6534.","journal-title":"Nat Commun"},{"issue":"12","key":"2744_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1586\/14760584.2014.969714","volume":"13","author":"SL Kurtz","year":"2014","unstructured":"Kurtz SL, Ravindranathan S, Zaharoff DA. Current status of autologous breast tumor cell-based vaccines. Expert Rev Vaccines. 2014;13(12):1439\u201345.","journal-title":"Expert Rev Vaccines"},{"key":"2744_CR13","doi-asserted-by":"crossref","unstructured":"Medina R, Wang H, Caisova V, Cui J, Indig IH, Uher O et al. Induction of Immune Response against metastatic tumors via vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 antibody (MBTA). Adv Ther (Weinh). 2020;3(9).","DOI":"10.1002\/adtp.202000044"},{"issue":"2","key":"2744_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1128\/CMR.00046-08","volume":"22","author":"TH Mogensen","year":"2009","unstructured":"Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240\u201373. Table of Contents.","journal-title":"Clin Microbiol Rev"},{"key":"2744_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.","journal-title":"Front Immunol"},{"issue":"3","key":"2744_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.chembiol.2021.10.012","volume":"29","author":"CL Miller","year":"2022","unstructured":"Miller CL, Sagiv-Barfi I, Neuhofer P, Czerwinski DK, Artandi SE, Bertozzi CR, et al. Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. Cell Chem Biol. 2022;29(3):451\u201362. e8.","journal-title":"Cell Chem Biol"},{"issue":"2","key":"2744_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/vaccines2020323","volume":"2","author":"DN Toussi","year":"2014","unstructured":"Toussi DN, Massari P. Immune Adjuvant Effect of molecularly-defined toll-like receptor ligands. Vaccines (Basel). 2014;2(2):323\u201353.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"2744_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17(2):175\u201386.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"2744_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20050749","volume":"202","author":"A Torosantucci","year":"2005","unstructured":"19Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med. 2005;202(5):597\u2013606.","journal-title":"J Exp Med"},{"issue":"3","key":"2744_CR20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1021\/bp0342093","volume":"20","author":"K Kato","year":"2004","unstructured":"Kato K, Itoh C, Yasukouchi T, Nagamune T. Rapid protein anchoring into the membranes of mammalian cells using oleyl chain and poly(ethylene glycol) derivatives. Biotechnol Progr. 2004;20(3):897\u2013904.","journal-title":"Biotechnol Progr"},{"key":"2744_CR21","doi-asserted-by":"crossref","unstructured":"Hu FX, Huang DH, Luo YX, Zhou PQ, Lv C, Wang KT et al. Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2019-000498"},{"key":"2744_CR22","doi-asserted-by":"crossref","unstructured":"Lin YN, Schmidt MO, Sharif GM, Vietsch EE, Kiliti AJ, Barefoot ME et al. Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity. Oncoimmunology. 2022;11(1).","DOI":"10.1080\/2162402X.2022.2027136"},{"key":"2744_CR23","doi-asserted-by":"crossref","unstructured":"Peng M, Mo YZ, Wang Y, Wu P, Zhang YJ, Xiong F et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1).","DOI":"10.1186\/s12943-019-1055-6"},{"issue":"2","key":"2744_CR24","first-page":"109","volume":"9","author":"Y Suhail","year":"2019","unstructured":"Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri R, et al. Syst Biology Cancer Metastasis Cell Syst. 2019;9(2):109\u201327.","journal-title":"Syst Biology Cancer Metastasis Cell Syst"},{"issue":"1","key":"2744_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh K, Massague J. Targeting metastatic cancer. Nat Med. 2021;27(1):34\u201344.","journal-title":"Nat Med"},{"issue":"8","key":"2744_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm1469","volume":"12","author":"PS Steeg","year":"2006","unstructured":"Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895\u2013904.","journal-title":"Nat Med"},{"key":"2744_CR27","doi-asserted-by":"crossref","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4).","DOI":"10.1038\/s41408-021-00459-7"},{"issue":"5","key":"2744_CR28","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"3","key":"2744_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the Tumor Microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31(3):311\u201325.","journal-title":"Cancer Cell"},{"issue":"9","key":"2744_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1084\/jem.20021787","volume":"197","author":"BN Gantner","year":"2003","unstructured":"Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2. J Exp Med. 2003;197(9):1107\u201317.","journal-title":"J Exp Med"},{"key":"2744_CR31","doi-asserted-by":"crossref","unstructured":"Li DY, Wu MH. Pattern recognition receptors in health and diseases. Signal Transduct Tar. 2021;6(1).","DOI":"10.1038\/s41392-021-00687-0"},{"key":"2744_CR32","doi-asserted-by":"crossref","unstructured":"Luchner M, Reinke S, Milicic A. TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics. 2021;13(2).","DOI":"10.3390\/pharmaceutics13020142"},{"key":"2744_CR33","doi-asserted-by":"crossref","unstructured":"Huang LL, Ge XY, Liu Y, Li H, Zhang ZY. The role of toll-like receptor agonists and their nanomedicines for Tumor Immunotherapy. Pharmaceutics. 2022;14(6).","DOI":"10.3390\/pharmaceutics14061228"},{"issue":"5","key":"2744_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","volume":"21","author":"DY Ma","year":"2009","unstructured":"Ma DY, Clark EA. The role of CD40 and CD154\/CD40L in dendritic cells. Semin Immunol. 2009;21(5):265\u201372.","journal-title":"Semin Immunol"},{"key":"2744_CR35","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.smim.2020.101435","volume":"49","author":"J Han","year":"2020","unstructured":"Han J, Khatwani N, Searles TG, Turk MJ, Angeles CV. Memory CD8(+) T cell responses to cancer. Semin Immunol. 2020;49:101435.","journal-title":"Semin Immunol"},{"issue":"8","key":"2744_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Sun Z, Chen L, Memory. T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020;11(8):549\u201364.","journal-title":"Protein Cell"},{"issue":"5","key":"2744_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11523-021-00840-3","volume":"16","author":"H Stege","year":"2021","unstructured":"Stege H, Haist M, Nikfarjam U, Schultheis M, Heinz J, Pemler S, et al. The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. Target Oncol. 2021;16(5):537\u201352.","journal-title":"Target Oncol"},{"issue":"1","key":"2744_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","volume":"52","author":"A Sledzinska","year":"2020","unstructured":"Sledzinska A, de Mucha MV, Bergerhoff K, Hotblack A, Demane DF, Ghorani E, et al. Regulatory T cells restrain Interleukin-2-and Blimp-1-Dependent Acquisition of cytotoxic function by CD4(+) T cells. Immunity. 2020;52(1):151\u2013.","journal-title":"Immunity"},{"issue":"11","key":"2744_CR39","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1007\/s00262-021-02920-9","volume":"70","author":"O Uher","year":"2021","unstructured":"Uher O, Caisova V, Padoukova L, Kvardova K, Masakova K, Lencova R, et al. Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. Cancer Immunol Immun. 2021;70(11):3303\u201312.","journal-title":"Cancer Immunol Immun"},{"issue":"3","key":"2744_CR40","first-page":"390","volume":"1","author":"CD Corso","year":"2011","unstructured":"Corso CD, Ali AN, Diaz R. Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res. 2011;1(3):390\u2013412.","journal-title":"Am J Cancer Res"},{"key":"2744_CR41","doi-asserted-by":"crossref","unstructured":"Huang L, Ge X, Liu Y, Li H, Zhang Z. The role of toll-like receptor agonists and their nanomedicines for Tumor Immunotherapy. Pharmaceutics. 2022;14(6).","DOI":"10.3390\/pharmaceutics14061228"},{"issue":"3","key":"2744_CR42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168\u201382.","journal-title":"Nat Rev Immunol"},{"key":"2744_CR43","doi-asserted-by":"crossref","unstructured":"Chen A, Neuwirth I, Herndler-Brandstetter D. Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized mice. Cancers (Basel). 2023;15(11).","DOI":"10.3390\/cancers15112989"},{"key":"2744_CR44","doi-asserted-by":"crossref","unstructured":"Chulpanova DS, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Mouse Tumor Models for Advanced Cancer Immunotherapy. Int J Mol Sci. 2020;21(11).","DOI":"10.3390\/ijms21114118"},{"issue":"7681","key":"2744_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512\u20136.","journal-title":"Nature"},{"issue":"3","key":"2744_CR46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41409-020-01060-5","volume":"56","author":"R Hong","year":"2021","unstructured":"Hong R, Zhao H, Wang Y, Chen Y, Cai H, Hu Y, et al. Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2021;56(3):570\u201380.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2744_CR47","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jcyt.2022.01.004","volume":"24","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, et al. Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. Cytotherapy. 2022;24(7):742\u20139.","journal-title":"Cytotherapy"},{"key":"2744_CR48","doi-asserted-by":"crossref","unstructured":"Watterson A, Coelho MA. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Cell Commun Signal. 2023;21(1).","DOI":"10.1186\/s12964-023-01063-x"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02744-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T03:19:41Z","timestamp":1689131981000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02744-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2744"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02744-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"11 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Cancer Institute (NCI) Animal Use and Care Committees approved the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the manuscript and agree to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflict of interest. Author SC is employed by NE1 Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}